IQVIA Holdings Inc. (NYSE:IQV) Stock Has Consensus Price Target of $274.31 According to Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has been assigned a consensus rating of “Moderate Buy” from the seventeen research firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $276.00.

IQV has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Barclays boosted their price target on shares of IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Mizuho upped their price target on shares of IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Wednesday, October 7th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $329.00 price objective (up from $300.00) on shares of IQVIA in a research note on Monday, September 28th.

IQVIA Stock Performance

Shares of NYSE IQV opened at $270.80 on Tuesday. The stock has a fifty day moving average price of $260.18 and a two-hundred day moving average price of $212.46. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The firm has a market cap of $44.57 billion, a P/E ratio of 33.60, a PEG ratio of 2.27 and a beta of 1.17. IQVIA has a 1 year low of $154.50 and a 1 year high of $277.40.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts forecast that IQVIA will post 11.56 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares in the company, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 15,581 shares of company stock valued at $3,796,021. Corporate insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several large investors have recently modified their holdings of IQV. BlackRock Inc. acquired a new stake in shares of IQVIA during the second quarter worth $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of IQVIA by 9.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after purchasing an additional 134,997 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of IQVIA by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock valued at $282,657,000 after purchasing an additional 66,643 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of IQVIA in the 2nd quarter valued at $240,911,000. Finally, Bank of America Corp DE acquired a new position in shares of IQVIA in the 2nd quarter valued at $235,551,000. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.